CD4 News and Research

RSS

TSRI scientists develop new drug candidate against HIV

In a remarkable new advance against the virus that causes AIDS, scientists from the Jupiter, Florida campus of The Scripps Research Institute have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine.

18 Feb 2015

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells.

10 Feb 2015

Researchers identify immune biomarkers that could help predict complications in HIV/TB patients

Doctors treating patients battling both HIV and tuberculosis (TB)--many of whom live in Africa--are faced with the decision when to start those patients on antiretroviral therapy (ART) while they are being treated with antibiotics for active TB disease. Some patients fare well on both interventions, with the immune system in check and the TB controlled.

10 Feb 2015

ABIVAX doses first HIV positive patient in ABX464 Phase IIa clinical trial

ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464.

2 Feb 2015

Researchers gain new insight on immune cells that harbor latent HIV virus

Drugs for HIV have become adept at suppressing infection, but they still can't eliminate it. That's because the medication in these pills doesn't touch the virus' hidden reserves, which lie dormant within infected white blood cells. Unlock the secrets of this pool of latent virus, scientists believe, and it may become possible to cure - not just control - HIV.

2 Feb 2015

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.

8 Jan 2015

Heroin use impacts HIV disease progression

Researchers at Yale and Boston University and their Russian collaborators have found that occasional heroin use by HIV-positive patients may be particularly harmful to the immune system and worsens HIV disease, compared to persistent or no heroin use.

15 Dec 2014

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.

2 Dec 2014

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust.

2 Dec 2014

Study finds that starting ART treatment soon after HIV infection improves immune health

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.

25 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well.

3 Nov 2014

Daktari receives NIH SBIR grant to develop point-of-care sickle cell diagnostic test

Daktari Diagnostics, in collaboration with Harvard University, the Medical University of South Carolina, and the University of Zambia in Lusaka, is thrilled to announce that it has been awarded a Small Business Innovation Research grant by the National Institute of Health for a point-of-care sickle cell diagnostic test.

23 Sep 2014

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.

8 Sep 2014

New blood test provides fast, accurate diagnosis of tuberculosis in children

A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children.

1 Sep 2014

Pilot study shows that anti-cancer drug can activate hidden HIV

A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV.

23 Jul 2014

HIV detected in Mississippi baby after apparent cure

In November 2013, it was reported that an infant (known as the “Mississippi baby”) had been in prolonged remission from HIV and was apparently cured. However, after 2 years without taking antiretroviral therapy and having no evidence of the virus, the child now has detectable levels of HIV.

11 Jul 2014

Mississippi baby: Infant seemingly cured of HIV has detectable levels of HIV

The child known as the "Mississippi baby"-an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall-now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case.

11 Jul 2014

GSMA announces mobile ecosystem partnership to provide mHealth services to women, children

The GSMA today announced that its Mobile for Development mHealth programme has launched a new cross-ecosystem partnership designed to provide a range of mHealth services to women and children, with a particular focus on nutrition, across Sub-Saharan Africa.

30 Jun 2014

Study finds link between high CD4 cell counts and reduced ischemic stroke risk in people with HIV

A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects.

24 Jun 2014